BioCentury
ARTICLE | Company News

Opko, Teva deal

October 6, 2008 7:00 AM UTC

Opko acquired exclusive, worldwide rights from Teva to develop and commercialize budesonide for ophthalmic indications including inflammation and allergic ocular conditions. Terms were not disclosed. ...